^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HMBD-002

    i
    Other names: HMBD-002, HMBD 002, HMBD-002-V4, HMBD-002-V4C26
    Associations

    News

    Trials
    Company:
    Hummingbird Biosci
    Drug class:
    VISTA antagonist
    Related drugs:
    Associations

    News

    Trials
    23d
    A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=313, Recruiting, Hummingbird Bioscience | N=240 --> 313 | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • PD-1 (Programmed cell death 1)
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • HMBD-002
    over2years
    Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. (PubMed, J Immunother Cancer)
    In conclusion, we have shown that VISTA-induced immune suppression can be reversed by blockade of the functional C-C' loop region of VISTA with a first-in-class rationally targeted and non-depleting IgG4 isotype anti-VISTA antibody, HMBD-002. This antibody represents a highly promising novel therapy in the VISTA-suppressed ICT non-responder population.
    Journal • IO biomarker
    |
    VSIR (V-Set Immunoregulatory Receptor)
    |
    HMBD-002
    almost3years
    A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab (clinicaltrials.gov)
    P1, N=240, Recruiting, Hummingbird Bioscience, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • PD-1 (Programmed cell death 1)
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • HMBD-002
    3years
    A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab (clinicaltrials.gov)
    P1, N=240, Not yet recruiting, Hummingbird Bioscience, Inc.
    Clinical • New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • PD-1 (Programmed cell death 1)
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • HMBD-002